SummaryFederal officials have quietly approved another generic version of the abortion pill mifepristone, sparking backlash from anti-abortion groups and Trump-aligned politicians. Drugmaker Evita Solutions announced FDA approval for its low-cost mifepristone, approved to end pregnancies up to 10 weeks. Critics condemned the move as a failure of the Trump administration’s promises. Read on to learn more about the approval, the controversy, and its impact on abortion.